Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. [electronic resource]
Producer: 19950223Description: 37-47 p. digitalISSN:- 0340-7004
- Adult
- Aged
- Animals
- Antibodies, Monoclonal -- adverse effects
- Antigen-Antibody Reactions
- Antigens, CD -- immunology
- Antigens, CD19
- Antigens, Differentiation, B-Lymphocyte -- immunology
- B-Lymphocytes -- immunology
- Combined Modality Therapy
- Complement System Proteins -- metabolism
- Cytotoxicity, Immunologic
- Dose-Response Relationship, Immunologic
- Female
- Humans
- Immunoglobulins -- blood
- Immunophenotyping
- Infusions, Intravenous
- Interleukin-2 -- adverse effects
- Leukocyte Count
- Lymphocyte Activation
- Lymphoma, Non-Hodgkin -- immunology
- Male
- Mice
- Middle Aged
- Receptors, Interleukin-2 -- metabolism
- Recombinant Proteins -- therapeutic use
- T-Lymphocytes -- immunology
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.